Neupharma, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Feb 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 9, 2027The maintenance fee for Certain chemical entities, compositions, and methods (US 10,344,048) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
- 1 fee due Apr 29, 2027The maintenance fee for Certain chemical entities, compositions, and methods (US 10,457,641) comes due Apr 29, 2027. Unpaid by Oct 29, 2027, it lapses early.
- 1 fee due May 26, 2027The maintenance fee for Certain steroids and methods for using the same in the treatment of cancer (US 10,487,108) comes due May 26, 2027. Unpaid by Nov 26, 2027, it lapses early.
- 2 fees due Jul 9 to 28, 2027 · next Jul 9
- 3 fees due Aug 2 to 18, 2027 · next Aug 2
- 2 fees due Sep 17 to 29, 2027 · next Sep 17
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,493,503 | Certain chemical entities, compositions, and methods In force · From the USPTO record | In force | From the USPTO record | |
| US 10,344,048 | Certain chemical entities, compositions, and methods In force · From the USPTO record | In force | From the USPTO record | |
| US 10,766,920 | Certain chemical entities, compositions, and methods In force · From the USPTO record | In force | From the USPTO record | |
| US 9,572,808 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer In force · From the USPTO record | In force | From the USPTO record | |
| US 10,137,125 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer In force · From the USPTO record | In force | From the USPTO record | |
| US 10,561,652 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer In force · From the USPTO record | In force | From the USPTO record | |
| US 9,518,029 | Certain chemical entities, compositions, and methods In force · From the USPTO record | In force | From the USPTO record | |
| US 9,822,081 | Certain chemical entities, compositions, and methods In force · From the USPTO record | In force | From the USPTO record | |
| US 10,065,932 | Certain chemical entities, compositions, and methods In force · From the USPTO record | In force | From the USPTO record | |
| US 10,759,766 | Certain chemical entities, compositions, and methods In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 35: 6 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 10 no status recorded